EXG 110
Alternative Names: EXG-110Latest Information Update: 18 Mar 2025
At a glance
- Originator Exegenesis Bio
- Class Gene therapies
- Mechanism of Action Alpha-galactosidase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Fabry's disease
Most Recent Events
- 18 Feb 2025 Hangzhou Jiayin Biotech plans a phase I/II trial for Fabry disease in China (IV, Injection) in March 2025 (NCT06819514)
- 10 Dec 2024 EXG 110 is available for licensing as of 10 Dec 2024. https://exegenesisbio.com/partnering-business-development/
- 03 Dec 2024 EXG 110 receives Orphan Drug status for Fabry's disease in USA